pharmaphorum| News & views on pharma and biotech’s evolving future

Patients

Sponsored

12 Questions with Kim Innes

Kim Innes is General Manager of Teva UK. She has more than 30 years’ experience across the pharmaceutical industry.

News

Tarsus places $800m wager on Alkeus' Stargardt therapy

Tarsus agrees to buy Alkeus in an $800m deal that will give it rights to a drug for eye disorder Stargardt disease with "blockbuster potential."

Oncology

Early onset cancer new approach treatment

News

Novo Nordisk wins Netherlands GLP-1 compounding lawsuit

A Dutch compounding pharmacy has been ordered to stop distributing a compounded nasal spray version of Novo Nordisk's GLP-1 agonist semaglutide.

News

Takeda's first-in-class narcolepsy drug claims FDA approval

Takeda's orexin agonist Orzeyful is the first drug approved in the US that can treat the "full range" of narcolepsy type 1 symptoms, says the FDA.

Featured Content

Market Access

Three separate injections - blue, red, and yellow - take off against black background

Why global pharmaceutical reforms are quietly redirecting ra...

Publication of the 2026 Pharma Package by the Council of the EU represents the most significant reform of EU pharmaceutical legislation in over 20 yrs

Oncology

Early onset cancer new approach treatment

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

R&D

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

R&D

Sponsored

Patient population first: the strategy behind country decisi...

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

Newsletters and Deep Dive
digital magazine

Latest News

News

Tarsus places $800m wager on Alkeus' Stargardt therapy

Tarsus agrees to buy Alkeus in an $800m deal that will give it rights to a drug for eye disorder Stargardt disease with "blockbuster potential."

News

Novo Nordisk wins Netherlands GLP-1 compounding lawsuit

A Dutch compounding pharmacy has been ordered to stop distributing a compounded nasal spray version of Novo Nordisk's GLP-1 agonist semaglutide.

News

Takeda's first-in-class narcolepsy drug claims FDA approval

Takeda's orexin agonist Orzeyful is the first drug approved in the US that can treat the "full range" of narcolepsy type 1 symptoms, says the FDA.

News

Senate confirms Erica ‌Schwartz as CDC Director

CDC has a permanent director in place at last, after the Senate confirmed Erica Schwartz's nomination to what has become a politically charged role.

Views & Analysis

Patients

Sponsored

12 Questions with Kim Innes

Kim Innes is General Manager of Teva UK. She has more than 30 years’ experience across the pharmaceutical industry.

Market Access

Why global pharmaceutical reforms are quietly redirecting ra...

Publication of the 2026 Pharma Package by the Council of the EU represents the most significant reform of EU pharmaceutical legislation in over 20 yrs

R&D

ESG considerations digitally overlain on green cityscape background

Integrate or isolate: Incorporating traditional safety-relat...

Should traditional safety considerations be treated as distinct from broader ESG frameworks, or fully integrated within them?

Sales & Marketing

What does FDA's proposed DTC advertising rule mean for pharm...

Last month, the FDA quietly added a proposed rule to the 2026 Unified Agenda that – if finalised – could make prescription drug advertising untenable.